You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
|
|---|---|
| Published in |
Journal of Experimental & Clinical Cancer Research, October 2009
|
| DOI | 10.1186/1756-9966-28-134 |
| Pubmed ID | |
| Authors |
Rafał Stec, Bartłomiej Grala, Michał Mączewski, Lubomir Bodnar, Cezary Szczylik |
| Abstract |
Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC). ChRCC is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman. Eighty six percent of ChRCCs cases are diagnosed in stage 1 or 2. Prognosis of ChRCC is better than in other types of RCC. Five- and 10-year disease free survival (DFS) for ChRCC was 83.9% and 77.9%, respectively. Expression of immunohistological markers: cytokeratins (CK), vimentin, epithelial membrane antigen (EMA), CD10 could be potentially helpful in diagnosis of different subtypes of RCC. From all conventional RCC, CD 117 was detected (overexpression) in membrane of cells ChRCC.Overexpression of CD117 on cellular membranes of ChRCC could be a potential target for kinase inhibitors like: imatinib, dasatinib, nilotinib. The potential targets for other kinase inhibitors (sunitinib and sorafenib) in ChRCC seem to be VEGFR and PDGFR. On the basis for formulating research hypotheses which should be verified by prospective studies. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 48 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 15% |
| Student > Ph. D. Student | 6 | 13% |
| Student > Postgraduate | 6 | 13% |
| Student > Bachelor | 5 | 10% |
| Other | 5 | 10% |
| Other | 9 | 19% |
| Unknown | 10 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 48% |
| Agricultural and Biological Sciences | 6 | 13% |
| Biochemistry, Genetics and Molecular Biology | 5 | 10% |
| Social Sciences | 1 | 2% |
| Mathematics | 1 | 2% |
| Other | 0 | 0% |
| Unknown | 12 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 February 2012.
All research outputs
#17,302,400
of 25,394,764 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#1,247
of 2,384 outputs
Outputs of similar age
#90,240
of 106,804 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#4
of 6 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,384 research outputs from this source. They receive a mean Attention Score of 4.8. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 106,804 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.